혈전 제거 디바이스 시장 규모는 2024년 16억 5,688만 달러에서 예측 기간 중 CAGR 6.83%로 추이하며, 2032년에는 28억 685만 달러에 달할 것으로 예측됩니다.
혈전 제거 장치에 대한 수요는 몇 가지 주요 요인에 의해 증가하고 있으며, 이는 시장의 강력한 성장을 지원하고 있습니다. 우선 급성 허혈성 뇌졸중, 폐색전증, 심부정맥혈전증(DVT) 등 신경질환 및 심혈관 질환의 전 세계적인 유병률이 증가하고 있으며, 신속하고 효과적인 개입이 요구되고 있습니다. 또한 환자와 의료진 모두 최소침습적 치료에 대한 선호도가 높아진 것도 그 배경이 되고 있습니다. 시장 성장을 더욱 가속화하고 있는 것은 주요 기업의 지속적인 혁신과 신제품 출시입니다. 이들 기업은 시술 효율과 치료 결과를 높이는 차세대 제품을 개발하기 위해 첨단 기술에 대한 투자를 강화하고 있습니다. 이러한 복합적인 추세로 인해 2025-2032년까지 시장은 지속적인 확장을 위한 유리한 환경에 놓여있다고 할 수 있습니다.
혈전 제거 장치: 시장 역학
영국심장재단(2024년)의 보고서에 따르면 전 세계에서 약 5,600만 명의 여성과 4,500만 명의 남성이 뇌졸중을 경험한 생존자이며, 이는 뇌혈관 질환의 전 세계적 부담이 얼마나 큰지 보여줍니다. 재단의 또 다른 보고서(2022년 기준)에 따르면 관상동맥질환 유병자 수가 전 세계에서 약 2억 5,000만 명에 달하고 있으며, 효과적인 인터벤션의 필요성이 더욱 부각되고 있습니다. 또한 세계뇌졸중기구(2023년) 자료에 따르면 25세 이상 성인 4명 중 1명이 평생 동안 뇌졸중을 경험할 것으로 예상되며, 이미 전 세계에서 1억 1,000만 명 이상이 뇌졸중을 앓은 적이 있다고 합니다. 혈전 제거 장치는 급성기 허혈성 뇌졸중이나 말초동맥 혈전증과 같은 생명과 직결되는 질환에서 동맥과 정맥의 막힘을 유발하는 혈전을 물리적으로 제거하여 혈류를 재개시키는데 매우 중요한 역할을 합니다.
호주 국립보건연구원(2022년) 자료에 따르면 호주에서는 매년 17,000명 이상이 정맥혈전색전증(VTE)을 앓고 있는 것으로 나타났습니다. 이러한 혈전 관련 질환 증가는 혈전 제거 장치와 같은 효과적인 치료 수단의 필요성을 더욱 강조하고 있습니다.
또한 영국 심장재단(2025년)의 최신 데이터에 따르면 2024년 기준 760만 명 이상의 영국인이 심장 및 순환기 질환을 앓고 있으며, 그 중 남성이 400만 명, 여성이 360만 명에 달할 전망입니다. 이 수치는 2030년까지 100만 명, 2040년에는 200만 명으로 늘어날 것으로 예상되며, 이러한 만성질환에 대처하기 위한 첨단 의료기술, 특히 혈전을 빠르게 제거하여 혈류를 회복시키는 장치에 대한 수요가 증가하고 있습니다.
또한 미국심장협회(2023년)의 보고에 따르면 미국에서는 1,200만 명 이상, 전 세계에서 2억 명 이상이 말초동맥질환(PAD)을 앓고 있는 것으로 추정됩니다. 이러한 PAD 사례의 급증으로 심장이나 뇌 이외의 동맥 막힘을 제거하기 위해 널리 사용되는 혈전제거장치에 대한 수요가 증가하고 있습니다. 이러한 저침습적 장치는 혈류 회복, 증상 완화, 장기적인 치료 결과 개선에 중요한 역할을 하고 있습니다.
세계의 혈전 제거 디바이스 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회의 분석, 법규제 환경, 시장 규모 추이·예측, 각종 구분·지역/주요 국가별 상세 분석, 경쟁 구도, 주요 기업의 개요 등을 정리하여 전해드립니다.
Thrombectomy Devices Market by Product (Mechanical Thrombectomy Devices, Aspiration Thrombectomy Devices, Ultrasonic Thrombectomy Devices, and Others), Application (Peripheral Vascular Thrombectomy, Coronary Vascular Thrombectomy, and Neurovascular Thrombectomy), End-User (Hospitals & Clinics, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the growing prevalence of neurological and cardiovascular diseases and increasing product development activities among the key market players.
The thrombectomy devices market was valued at USD 1,656.88 million in 2024, growing at a CAGR of 6.83% during the forecast period from 2025 to 2032 to reach USD 2,806.85 million by 2032. The growing demand for thrombectomy devices is driven by several key factors supporting strong market growth. The rising global prevalence of neurological and cardiovascular conditions such as acute ischemic stroke, pulmonary embolism, and deep vein thrombosis, among others necessitate timely, effective interventions. Additionally, there is a clear shift toward minimally invasive treatment options, preferred by both patients and healthcare providers. Further fueling growth in the market is the continuous innovation and product launches by leading players, which are investing in advanced technologies and launching next-generation products that enhance procedural efficiency and outcomes. Collectively, these trends are creating a favorable environment for sustained market expansion from 2025 to 2032.
Thrombectomy Devices Market Dynamics:
According to the British Heart Foundation (2024), an estimated 56 million women and 45 million men worldwide were stroke survivors, reflecting the immense global burden of cerebrovascular disease. The same source also reported that, as of 2022, nearly 250 million people globally were living with coronary heart disease, further emphasizing the need for effective interventional solutions. Similarly, data from the World Stroke Organization (2023), highlighted that one in four adults over the age of 25 would suffer a stroke in their lifetime, and over 110 million individuals worldwide had already experienced one. Thrombectomy devices play a vital role in restoring blood flow by physically removing blood clots that obstruct arteries or veins, especially in acute, life-threatening conditions such as ischemic stroke or peripheral arterial thrombosis.
According to data from the National Institute of Health (2022), over 17,000 individuals in Australia develop venous thromboembolism (VTE) annually. This rising burden of blood clot-related conditions underscores the critical need for effective treatment options like thrombectomy devices.
Recent data from the British Heart Foundation (2025) revealed that, in 2024, more than 7.6 million people in the UK were living with heart and circulatory diseases, including over 4 million men and 3.6 million women with projections indicating that this number was expected to grow by 1 million by 2030, and by 2 million by 2040, highlighting the increasing demand for advanced medical technologies to manage these conditions, particularly devices that can promptly remove dangerous clots and restore blood flow.
Moreover, data from the American Heart Association (2023), reported that more than 12 million Americans, along with 200 million individuals globally, were suffering from peripheral artery disease (PAD). This alarming rise in PAD cases is fueling demand for thrombectomy devices, which are widely used to clear blockages in arteries outside the heart and brain. These minimally invasive devices play a crucial role in restoring circulation, alleviating symptoms, and improving long-term patient outcomes.
Further, key market players are intensifying their R&D efforts to develop and commercialize next-generation thrombectomy systems. For instance, in March 2025, Inari Medical (part of Stryker) launched the Artix(TM) Thrombectomy System, an integrated platform combining aspiration and mechanical thrombectomy for peripheral arterial disease. This next-generation device offers enhanced procedural control and versatility, expanding treatment options for patients with arterial thromboembolic conditions.
In April 2024, AngioDynamics received FDA clearance for its AlphaVac F1885 System to treat pulmonary embolism (PE), expanding its use beyond general thrombectomy. This minimally invasive device offers a mechanical solution for removing blood clots, improving clinical outcomes and safety for PE patients. The clearance, supported by strong clinical trial results, is expected to drive market growth by broadening treatment options and enhancing procedural efficiency.
However, the risk and complications associated with thrombectomy procedures and the strict regulatory approvals and compliance requirements, among others are some of the key constraints that may limit the growth of the thrombectomy devices market.
Thrombectomy Devices Market Segment Analysis:
Thrombectomy Devices Market by Product (Mechanical Thrombectomy Devices, Aspiration Thrombectomy Devices, Ultrasonic Thrombectomy Devices, and Others), Application (Peripheral Vascular Thrombectomy, Coronary Vascular Thrombectomy, and Neurovascular Thrombectomy), End-User (Hospitals & Clinics, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the product segment of the thrombectomy devices market, the mechanical thrombectomy devices category is estimated to account for the largest market share in 2024. This can be primarily attributed to the rising prevalence of cardiovascular disorders (CVDs) such as strokes. Additionally, various advantages and applications provided by these devices could also raise the demand for the category.
A major factor driving this segment is the rising global prevalence of peripheral vascular and thrombotic disorders, such as peripheral artery disease (PAD), stroke, deep vein thrombosis (DVT), and pulmonary embolism (PE). According to the British Heart Foundation (2024), over 110 million individuals were affected by peripheral arterial (vascular) disease, while 94 million people globally were living with the effects of stroke. Similarly, the Global Stroke Factsheet (2022), stated that the risk of developing a stroke has increased by 50% over the last 17 years and now 1 in 4 people is estimated to have a stroke in their lifetime. According to the same source, globally 101 million people were suffering from stroke. Thus, the increasing prevalence of CVDs will create a need for the treatment of such disorders leading to the increasing demand for mechanical thrombectomy devices. These figures highlight the urgent need for effective clot-removal solutions often performed by mechanical thrombectomy devices.
One of the key clinical benefits of mechanical thrombectomy is its ability to rapidly restore blood flow, a feature that is especially crucial in life-threatening conditions such as acute ischemic stroke. The minimally invasive design of these devices typically introduced through a small puncture site offers several patient-centric advantages, including shorter hospital stays, quicker return to function, and lower complication rates when compared to open surgery.
Mechanical thrombectomy devices are specialized tools designed to remove blood clots from blood vessels. These devices are primarily used in treating conditions like ischemic stroke, deep vein thrombosis (DVT), and peripheral artery disease. These devices can quickly remove clots, restoring blood flow to affected areas and reducing the risk of long-term damage. In cases of ischemic stroke, this can be crucial in minimizing neurological deficits.
Additionally, by directly targeting and removing the clot, mechanical thrombectomy can reduce the risk of secondary complications like distal embolization (where parts of the clot break off and cause further blockages) and reocclusion (where the vessel becomes blocked again). Further, thrombectomy devices offer precise control over clot removal, which can be particularly advantageous in complex cases where other methods might be less effective or more risky.
Furthermore, various companies are conducting research and development related to thrombectomy devices to increase their product portfolio. For instance, in May 2023, Akura Medical, a Shifamed portfolio company initiated its first-in-human clinical study of the Akura mechanical thrombectomy device. The Akura platform is a low-profile solution designed to easily access and efficiently remove large volume, mixed morphology clots, and eliminate the guesswork around the procedure. Similarly, in April 2025, Surmodics announced the commercial launch of the Pounce(TM) XL Thrombectomy System. This next-generation device was designed for the rapid, non-surgical extraction of acute or chronic clots from the iliac and femoral arteries, eliminating the need for thrombolytic drugs. Such advancements address the critical need for safer, more efficient clot removal options, particularly for patients who are not suitable for thrombolytic therapy.
Thus, the factors mentioned above are likely to boost the market segment and thereby increase the overall market of thrombectomy devices across the globe.
North America is expected to dominate the overall thrombectomy devices market:
North America is expected to hold the largest share of the thrombectomy devices market in 2024, driven by several key factors. The region's dominance can be attributed to the high prevalence of neurovascular, peripheral, and coronary vascular diseases, the rapidly growing geriatric population, and the continuous innovation and product launches by leading medical device companies based in the region. These elements, combined with advanced healthcare infrastructure, favorable reimbursement policies, and increasing awareness of minimally invasive procedures, are expected to sustain North America's leading position in the global market.
According to data from the Centers for Disease Control and Prevention (2024), over 795,000 individuals in the United States experience a stroke each year. Notably, nearly 185,000 of these strokes, accounting for approximately 1 in 4 cases occur in individuals with a history of prior strokes. Additionally, the CDC reported that approximately 900,000 people in the U.S. were affected by venous thromboembolism (VTE) annually, further underlining the substantial burden of thromboembolic diseases. These increasing figures highlighted the growing need for thrombectomy devices, which are designed to physically remove blood clots and restore normal circulation in affected vessels thereby escalating the overall market across the region.
The prevalence of coronary heart disease (CHD) is also a major driver of market growth. According to CDC data from June 2024, around 20.5 million Americans were living with CHD as of 2022. Furthermore, an estimated 6.5 million individuals aged 40 and older were diagnosed with peripheral artery disease (PAD) in the same year. These increasing figures highlight the growing need for thrombectomy devices, which are designed to physically remove blood clots and restore normal circulation in affected vessels.
In addition to rising disease prevalence, North America market is also benefiting from technological innovation and new product launches. For instance, in September 2024, Vesalio announced the U.S. commercialization of the pVasc(TM) Thrombectomy System, a device designed for the non-surgical removal of peripheral occlusions. The pVasc(TM) system targets a wide range of emboli, from soft, acute clots to fibrin-rich, calcified ones, providing a fast, safe, and versatile treatment option. Such developments not only enhance treatment efficacy but also expand the range of conditions that can be managed with thrombectomy devices.
Thrombectomy Devices Market Key Players:
Some of the key market players operating in the thrombectomy devices market include Stryker, Abbott Laboratories, Boston Scientific Corporation, Argon Medical Devices, Contego Medical, Inc., Mermaid Medical, Surmodics, Inc., Penumbra, Inc., Medtronic, Johnson & Johnson Services, Inc., Edwards Lifesciences Corporation, Terumo Corporation, Koninklijke Philips N.V., MicroPort Scientific Corporation, Thrombolex, phenox GmbH, Acandis GmbH, Inova, Vesalio Inc., ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD., and others.
Recent Developmental Activities in the Thrombectomy Devices Market:
Key takeaways from the thrombectomy devices market report study
Target audience who can benefit from this thrombectomy devices market report study
Frequently Asked Questions for the Thrombectomy Devices Market: